Cappella Promotes Sideguard & Serial IVUS Analysis at JIM 2010

GALWAY, Ireland, February 19, 2010 - Cappella, Inc. (Cappella, www.cappella-med.com/), a medical device
company developing dynamic solutions for the treatment of coronary
bifurcation disease, promoted their serial IVUS analysis & Sideguard(R) 3.25
(www.cappella-med.eu/index.php?option=com_content&view=article&id=1&Itemid=2) device during the Joint Interventional Meeting (JIM) in Rome. Gary S.
Mintz, MD, Cardiovascular Research Foundation, New York, USA presented
"Positive Vessel Remodeling Using Sideguard in Coronary Bifurcations" during
the New Technologies 1 Symposium. Dr. Mintz highlighted that serial IVUS &
OCT are ongoing in the Sideguard 3 study to confirm the initial findings of
Sideguard 1 (
www.cappella-med.eu/index.php?option=com_content&view=article&id=9&Itemid=14) and assess stent strut coverage. The IVUS sub-study results from
Sideguard 1 were published in the American Journal of Cardiology in October
2009.

The newest addition to the Sideguard portfolio, the Sideguard 3.25, was
implanted successfully in a live case performed by Ralf Mueller, MD,
Siegburg, Germany. According to Dr. Mueller, "We implanted the Sideguard 3.25
stent together with a 3,0mm DES in a Medina 0,1,1 LAD/D1 stenosis.
Positioning was easy and precise and IVUS demonstrated excellent scaffolding
at the bifurcation. The use of the Sideguard device made this bifurcation
intervention easy and predictable with an optimal acute result."

Martin B. Leon, MD, Founder & Director of Transcatheter Cardiovascular
Therapeutics (TCT) and Scientific Advisory Board (
www.cappella-med.eu/index.php?option=com_content&view=article&id=187:scientific-advisory-board&catid=4) member of Cappella assisted with the case.
Dr. Leon expressed his satisfaction with the device, "It was the first time I
used the 3.25 & I was very pleased with the outcome of the case."

(Due to the length of these URLs, it may be necessary to copy and paste
this hyperlink into your Internet browser's URL address field. Remove the
space if one exists.)

About Cappella, Inc.

Cappella, Inc. is a medical device company, developing novel solutions
for the treatment of complex Coronary Artery Disease (CAD) and specifically
bifurcation vascular disease. Cappella's initial product, the Sideguard(R)
Coronary Sidebranch Stent & Delivery System offers interventional
cardiologists a straightforward, effective solution that focuses on treating
the sidebranch of diseased coronary arteries first, rather than the main
vessel. More importantly, it allows the preferred stent of choice for the
main vessel. An optimal stent design specific to the anatomy of the
sidebranch, combined with the qualities of Nitinol now provide a dynamic
solution for treating sidebranch disease. Cappella Medical Devices Ltd.,
Galway, Ireland is the R&D and manufacturing subsidiary of Cappella, Inc. For
more information, see: www.cappella-med.com.

Contact: Claire Marie Gigon, Cappella Medical Devices Limited, Tel: +41(0)79-374-57-65, Email: cmgigon at cappella.ie